Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?

European Journal of Cancer

Volumn 43, Issue 15, 2007, Pages 2270-2278

  Biganzoli, Laura ^a   Licitra, Sara ^a   Claudino, Wederson ^a   Pestrin, Marta ^a   Leo, Angelo Di ^a  

^a HOSPITAL OF PRATO   (Italy)

Author keywords

Aromatase inhibitors; Breast cancer; Elderly patient; Phase III studies; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

ADVANCED CANCER; ALOPECIA; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG FATALITY; DRUG SAFETY; EARLY CANCER; ENDOMETRIUM CANCER; FOLLOW UP; FRACTURE; GERIATRIC PATIENT; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOT FLUSH; HUMAN; INSOMNIA; LUNG EMBOLISM; MEDICAL DECISION MAKING; METASTASIS; MYALGIA; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DECISION MAKING; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN;

EID: 35148853738     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.007     Document Type: Article

References (36)

1. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18 (2000) 3758-3767
2. Bonneterre J., Thurlimann B., Robertson J.F.R., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficay and Tolerability study. J Clin Oncol 18 (2000) 3748-3757
3. Bonneterre J., Buzdar A., Nabholtz J.M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 (2001) 2247-2258
4. Paridaens R., Therasse P., Dirix L., et al. First line hormonal treatment (HT) for metastatic breast cancer (BMC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) : a randomized phase III trial of the EORTC Breast Group. J Clin Oncol 22 14S (2004) abstract 515
5. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003) 2101-2109
6. Nabholtz J.M., Bonneterre J., Buzdar A., Robertson J.F., and Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39 (2003) 1684-1689
7. Mauri D., Pavlidis N., Polyzos N.P., and Ioannidis J.P.A. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98 (2006) 1285-1291
8. Karnon J. Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness. Pharmacoeconomics 24 (2006) 215-232
9. Venturino A., Comandini D., Granetto C., et al. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability. Breast Cancer Res Treat. 62 (2000) 217-222
10. Smith I., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. on behalf of IMPACT trialists. J Clin Oncol. 23 (2005) 5108-5116
11. Cataliotti L., Buzdar A., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106 (2006) 2095-2103
12. Semiglazov V.F., Kletsel A., Semiglazov V.V., et al. Exemestane (E) vs Tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1,T4N0M0). J Clin Oncol 23 16S (2005) 530
13. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
14. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
15. Dowset M., Allred D.C., et al. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 100 Suppl 1 (2006) S21 abstract 48
16. The ATAC Trialists' Group. Anastrozol alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
17. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
18. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
19. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 369 (2007) 559-570
20. Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuavant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early stage breast cancer: a meta-analysis. Lancet 7 (2006) 991-996
21. Goss P.E., Ingle J.N., Martino S., et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
22. Goss P.E., Ingle J.N., Martino S., et al. Randomised trial of letrozole following tamoxifen as adjuvant therapy in receptor-positive breast cancer: update findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
23. Ingle J., Du T., Shepherd L., Palmer M., Pater J., and Goss P. NCI CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. J Clin Oncol 24 15S (2006) abstract 549
24. Jakesz R., Samonigg H., Greil R., et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 23 10S (2005) abstract 527
25. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 23 (2005) 619-629
26. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anstrozole after 2 years' adjuvant tamoxifen : combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
27. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
28. Muss H.B., Tu D., Ingle J.N., et al. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat 100 Suppl 1 (2006) S23 abstract 102
29. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet 8 (2007) 119-127
30. Gass M., and Dawson-Hughes B. Preventing osteoporosis-related fracture: an overview. Am J Med 119 Suppl 1 (2006) S3-S11
31. The Arimidex Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
32. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer/ preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23 (2005) 5138-5147
33. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
34. Kennecke H.F., Olivotto I.A., Speers C., et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18 (2007) 45-51
35. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829-836
36. Lewis J.H., Kilgore M.L., Goldman D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 21 (2003) 1383-1389